Premium
Combination chemotherapy with vinblastine, bleomycin, and cis‐diamminedichloroplatinum (ii) in squamous cell carcinoma of the head and neck
Author(s) -
Brown Archie W.,
Blom Johannes,
Butler William M.,
GarciaGuerrero Guillermo,
Richardson Madison F.,
Henderson Robert L.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800601)45:11<2830::aid-cncr2820451119>3.0.co;2-#
Subject(s) - medicine , surgery , vinblastine , chemotherapy , radiation therapy , bleomycin , regimen , creatinine , combination chemotherapy , induction chemotherapy , urology , gastroenterology
Forty‐five patients with advanced squamous cell carcinoma of the head and neck, 23 of whom had received no prior therapy, were given the combination of vinblastine, 4 mg/m 2 intravenously (IV) on Day 1; bleomycin, 15 mg/day intramuscularly on Days 1–7; and cis‐diamminedichloroplatinum (II), 60 mg/m 2 with mannitol diuresis on Day 8. The regimen was repeated at three‐week intervals, for a maximum of three cycles. Among the 23 patients without prior surgery or radiation, there were 5 complete responses and 12 partial responses, a 74% response rate; whereas, among the 22 with prior therapy, there were 2 complete responses and 8 partial responses, a response rate of 45%. Nineteen of 23 previously untreated patients were subsequently given radiation, 1 had surgery, and 1 had surgery plus radiation. Twelve of these 19 patients are currently free of disease, with a median duration of ten months from initial response. Four of the 22 previously treated patients received radiation and 2, surgery; 4 of these 6 patients are without evidence of disease. Renal dysfunction with elevation of serum creatinine occurred in 5 patients, a leukocyte count of less than 3,000/mm 3 in 3, a platelet count of less than 100,000/mm 3 in 2, skin changes in 11, hearing loss in 1, and both peripheral neuropathy and pulmonary changes in 1 patient. This combination of agents has substantial activity in untreated patients and may be useful as initial therapy in advanced head and neck malignancies by diminishing the incidence of local recurrence and distant metastasis.